1
|
Yuri T, Kono Y, Okada T, Terada T, Miyauchi S, Fujita T. Transport Characteristics of 5-Aminosalicylic Acid Derivatives Conjugated with Amino Acids via Human H +-Coupled Oligopeptide Transporter PEPT1. Biol Pharm Bull 2020; 43:697-706. [PMID: 32238712 DOI: 10.1248/bpb.b19-01048] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
5-Aminosalicylic acid (5-ASA) is used as first line therapy for symptom remission and maintenance of inflammatory bowel disease (IBD). Because 5-ASA is well absorbed from the small intestine when orally administered, several 5-ASA formulations for selective delivery to the colon have been developed and used in clinical practice. However, its delivery efficiency to local inflamed colonic sites remains low. Intestinal H+-coupled oligopeptide transporter 1 (PEPT1) expression in the colon is low, whereas its expression is induced in the colon under chronic inflammation conditions, such as IBD. Therefore, we considered that PEPT1 would be a target transporter to improve 5-ASA delivery efficiency to local colonic lesions. We evaluated the transport characteristics of dipeptide-like 5-ASA derivatives, which were coupling glycine (Gly), lysine, glutamic acid (Glu), valine (Val) and tyrosine to amino or carboxyl group of 5-ASA, in Caco-2 cells. [3H]Glycylsarcosine (Gly-Sar) uptake into Caco-2 cells was inhibited by all 5-ASA derivatives. In addition, 5-ASA derivatives (Gly-ASA, Glu-ASA and Val-ASA), which were coupled by glycine, glutamic acid and valine to amino group of 5-ASA, were taken up in a pH- and concentration-dependent manner and their uptake was inhibited by excess Gly-Sar. Two-electrode voltage-clamp experiment using human PEPT1 expressing Xenopus oocytes showed that Gly-ASA, Glu-ASA and Val-ASA induced marked currents at pH 6.0. Taken together, these results showed that these 5-ASA derivatives are transportable substrates for PEPT1.
Collapse
Affiliation(s)
- Tatsushi Yuri
- Graduate School of Pharmaceutical Sciences, Ritsumeikan University
| | - Yusuke Kono
- Ritsumeikan Global-Innovation Research Organization (R-GIRO), Ritsumeikan University.,College of Pharmaceutical Sciences, Ritsumeikan University
| | - Tomofumi Okada
- College of Pharmaceutical Sciences, Ritsumeikan University
| | - Tomohiro Terada
- Department of Pharmacy, Shiga University of Medical Science Hospital
| | | | - Takuya Fujita
- Graduate School of Pharmaceutical Sciences, Ritsumeikan University.,Ritsumeikan Global-Innovation Research Organization (R-GIRO), Ritsumeikan University.,College of Pharmaceutical Sciences, Ritsumeikan University
| |
Collapse
|
2
|
Shahdadi Sardo H, Saremnejad F, Bagheri S, Akhgari A, Afrasiabi Garekani H, Sadeghi F. A review on 5-aminosalicylic acid colon-targeted oral drug delivery systems. Int J Pharm 2019; 558:367-379. [PMID: 30664993 DOI: 10.1016/j.ijpharm.2019.01.022] [Citation(s) in RCA: 51] [Impact Index Per Article: 10.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2018] [Revised: 01/08/2019] [Accepted: 01/08/2019] [Indexed: 02/08/2023]
Abstract
Site-specific colon drug delivery is a practical approach for the treatment of local diseases of the colon with several advantages such as rapid onset of action and reduction of the dosage of the drug as well as minimization of harmful side effects. 5-aminosalicylic acid (5-ASA) is a drug of choice in the treatment of inflammatory bowel disease and colitis. For the efficient delivery of this drug, it is vital to prevent 5-ASA release in the upper part of the gastrointestinal tract and to promote its release in the proximal colon. Different approaches including chemical manipulation of drug molecule for production of prodrugs or modification of drug delivery systems using pH-dependent, time-dependent and/or bacterially biodegradable materials have been tried to optimize 5-ASA delivery to the colon. In the current review, the different strategies utilized in the design and development of an oral colonic delivery dosage form of 5-ASA are presented and discussed.
Collapse
Affiliation(s)
- Hossein Shahdadi Sardo
- Targeted Drug Delivery Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran; Department of Pharmaceutics, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
| | - Farinaz Saremnejad
- Department of Food Science and Technology, Ferdowsi University of Mashhad, Mashhad, Iran
| | - Sara Bagheri
- Department of Pharmaceutics, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
| | - Abbas Akhgari
- Targeted Drug Delivery Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran; Department of Pharmaceutics, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.
| | - Hadi Afrasiabi Garekani
- Pharmaceutical Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran; Department of Pharmaceutics, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
| | - Fatemeh Sadeghi
- Targeted Drug Delivery Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran; Department of Pharmaceutics, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.
| |
Collapse
|
3
|
Kesisoglou F, Zimmermann EM. Novel drug delivery strategies for the treatment of inflammatory bowel disease. Expert Opin Drug Deliv 2005; 2:451-63. [PMID: 16296767 DOI: 10.1517/17425247.2.3.451] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
Inflammatory bowel disease (IBD) encompasses two idiopathic inflammatory diseases of the intestinal tract: Crohn's disease and ulcerative colitis. Existing therapy for IBD consists mainly of orally or rectally administered small drug molecules, such as 5-aminosalicylates and corticosteroids, or potent systemic immune suppressants. IBD presents a challenging target for drug delivery, particularly by the oral route, as, contrary to most therapeutic regimens, minimal systemic absorption and maximal intestinal wall drug levels are desired. Several delivery strategies are employed to achieve this goal, including the chemical modification of the drug molecules, the use of controlled- and delayed-release formulations and the use of bioadhesive particles. The goal of this review is to summarise existing IBD therapy and examine novel approaches in intestinal drug delivery.
Collapse
Affiliation(s)
- Filippos Kesisoglou
- University of Michigan Department of Pharmaceutical Sciences, College of Pharmacy, Ann Arbor, MI 48109-1065, USA
| | | |
Collapse
|
4
|
Palumbo G, Bacchi S, Primavera L, Palumbo P, Carlucci G. A validated HPLC method with electrochemical detection for simultaneous assay of 5-aminosalicylic acid and its metabolite in human plasma. Biomed Chromatogr 2005; 19:350-4. [PMID: 15586374 DOI: 10.1002/bmc.456] [Citation(s) in RCA: 39] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
A high-performance liquid chromatographic method was developed, validated and applied to the simultaneous determination of 5-aminosalicylic acid (5-ASA) and its acetylated metabolite (acetyl-5-ASA) in human plasma. The method involves liquid-liquid extraction with methanol followed by isocratic reversed-phase chromatography on a Kromasil KR100 C(18) column with electrochemical detection. The recovery, selectivity, linearity, precision and accuracy of the method were evaluated from spiked human plasma samples. The effects of mobile phase composition, buffer concentration, mobile phase pH and concentration of organic modifiers on retention of 5-ASA, acetyl 5-ASA and internal standard were investigated. Limits' of detection were 5 ng/mL for 5-ASA and 10 ng/mL for acetyl-5-ASA, respectively. The method can be used for supporting therapeutical drug monitoring and pharmacokinetic studies.
Collapse
Affiliation(s)
- Giancarlo Palumbo
- Dipartimento di Medicina Interna, Facoltà di Medicina, Università degli Studi di L'Aquila, Italy.
| | | | | | | | | |
Collapse
|
5
|
Simões JC, Santis PB, Gama RR, Bini AL, Cardoso MB, Repka JC. Colostomia tipo hartmann em ratos: alterações morfológicas e dosagem de hidroxiprolina. Rev Col Bras Cir 2000. [DOI: 10.1590/s0100-69912000000400005] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
A colostomia tem sido um procedimento cirúrgico freqüentemente empregado nas doenças colônicas, lesões traumáticas e neoplásicas. Este trabalho experimental, em ratos, visou estudar as progressivas mudanças morfológicas no cólon proximal e distal , após uma laparotomia e colostomia terminal, tipo Hartmann, que foram estudadas histologicamente e através da dosagem tecidual de hidroxiprolina. Utilizaram-se 40 ratos, machos, raça Wistar, com peso médio de 200 gramas, alocados em dois grupos (grupo I ou experimento e grupo II ou controle), subdivididos em quatro subgrupos: A,B,C e D com 10 animais em cada subgrupo. Os animais do grupo I (subgrupos A e B) foram submetidos à colostomia tipo Hartmann, no cólon distal, a 7,5cm do canal anal. Nos ratos do grupo II foi praticada apenas uma laparotomia mediana. Os animais dos subgrupo A e C foram sacrificados no 30º dia de P.O., enquanto que os animais dos subgrupos B e D o sacrifício foi no 60º dia de P.O. A análise histológica dos segmentos colônicos permitiu observar infiltrado inflamatório agudo e crônico na lâmina própria, achatamento pronunciado das criptas, diminuição do número de criptas e da celularidade epitelial, redução das células caliciformes e da mucossecreção, adelgaçamento da muscular da mucosa, mais intensos no coto colônico distal dos animais submetidos à colostomia terminal tipo Hartmann (subgrupos A e B). Os segmentos proximais apresentavam estas alterações, porém mais discretas. A dosagem de hidroxiprolina nos tecidos colônicos não revelou alterações estatisticamente significativas quanto ao conteúdo de colágeno ou do peso desidratado. Estes achados permitem demonstrar alterações morfológicas inflamatórias e hipotróficas mais pronunciadas no cólon distal de ratos submetidos à colostomia tipo Hartmann.
Collapse
|
6
|
Affiliation(s)
- C S Leopold
- Institut für Pharmazeutische Technologie, Düsseldorf
| |
Collapse
|
7
|
Chung MC, Gonçalves MF, Colli W, Ferreira EI, Miranda MT. Synthesis and in vitro evaluation of potential antichagasic dipeptide prodrugs of primaquine. J Pharm Sci 1997; 86:1127-31. [PMID: 9344169 DOI: 10.1021/js970006v] [Citation(s) in RCA: 22] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
American trypanosomiasis (Chagas' disease) is an endemic parasitic disease afflicting more than 20 million people in Latin America. Currently, therapy is unsatisfactory and only two drugs are available. Primaquine, an antimalarial drug, has trypanocidal activity. Dipeptide derivatives of primaquine, Phe-Arg-PQ, Lys-Arg-PQ, and Phe-Ala-PQ, were synthesized. The choice of the peptides was based on the primary specificity of cruzipain, the major cysteine proteinase from T cruzi. The prodrugs obtained were tested on the LLC-MK2 cell culture infected with trypomastigotes forms of T. cruzi. Phe-Arg-PQ, Lys-Arg-PQ, and Phe-Ala-PQ were active in all stages.
Collapse
Affiliation(s)
- M C Chung
- Departamento de Fármacos e Medicamentos, Faculdade de Ciéncias Farmacêuticas-UNESP-Araraquara, São Paulo, Brazil
| | | | | | | | | |
Collapse
|
8
|
|
9
|
|
10
|
Leopold CS, Friend DR. In vivo pharmacokinetic study for the assessment of poly(L-aspartic acid) as a drug carrier for colon-specific drug delivery. JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS 1995; 23:397-406. [PMID: 8882747 DOI: 10.1007/bf02353640] [Citation(s) in RCA: 25] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
Glucocorticoids remain one of the mainstays of therapy for acute attacks of inflammatory bowel disease despite systemic side effects that limit their use. Prodrugs that selectively deliver glucocorticoids to the colon may lower the required dose and side effects. Because enzymes of gut microflora are able to cleave certain peptide and ester bonds, the ability of an ester prodrug consisting of dexamethasone (DX) as model drug and poly(L-aspartic acid) (weight-average mol wt = 30,000) as drug carrier was investigated to selectively release the drug in the large intestine. Prodrug and drug solutions (1.18 mg DX/ml DMSO) were administered to two groups of male Sprague-Dawley rats by intragastric infusion using an ALZET osmotic pump. All rats were infused for sufficient time to achieve steady state in both blood and GI-tract tissues. DX concentrations in blood and tissue samples were measured with HPLC. The steady state DX concentrations at these sites were used to calculate a drug delivery index (DDI). DX blood concentrations were significantly lower (p < 0.05) after intragastric administration of the prodrug. Moreover, prodrug administration resulted in significantly higher DX concentrations in the cecum and colon mucosa and the cecum muscle tissue compared to DX administration (p < 0.05). The prodrug led to an increase of the DX concentration in the large intestinal tissues by factors of 1.3-2.0 and to an 1.3-fold decrease of DX blood concentrations. Thus, this novel conjugate should both increase efficacy and reduce toxicity to some extent.
Collapse
Affiliation(s)
- C S Leopold
- Controlled Release and Biomedical Polymers Department, SRI International, Menlo Park, California, USA
| | | |
Collapse
|